著者

鈴木 正彦 荒井 千春 手塚 春樹 中澤 美科 田中 睦子 河野 健治 花輪 剛久 中島 新一郎

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.6, pp.623-629, 2002-12-10 (Released:2011-03-04)

参考文献数

7

---

Regarding the management of blood preparations, since September 1995 the Ministry of Heath, Labour and Welfare has had to make and/or to keep documentary records such as the product name, date of dispensing, the patient's name and lot number and so on. At Yamanashi Medical University Hospital, to cope with deleterious accidents caused by blood preparations, we developed a new system for the management of blood preparations. This system consists of a printing system for confirmation labels for blood prescriptions and a computerized management system concerning the medication. In this study, the effect of this new management system on the rational use of blood preparations was evaluated. Compared with the former system, the time required to dispense blood preparations decreased from about 500 to 170 seconds per case. Furthermore, based on a questionnaire to medical doctors and/or nurses, it appeared that this system could reduce the time required to manage blood preparations and improve the rational use of injectable drugs.

著者

田中 睦子 河野 健治 花輪 剛久 鈴木 正彦 中島 新一郎

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.2, pp.152-156, 2002-04-10 (Released:2011-03-04)

参考文献数

12

---

Di-2-ethylhexyl Phthalate (DEHP) was reported to dissolve from a polyvinyl chloride (PVC) administration tube during the infusion of an injection fluid containing a solvilizing agent, soybean oil or lecithin, etc. This paper describes the behavior of DEHP dissolution from PVC tubes during enteral tube feeding. The DEHP concentration was determined using HPLC. After the passage the ENSURE LIQUID® (EL) solution through the PVC tube, DEHP was dissolved in the EL solution. The EL solution is one type of enteral nutrition. This dissolution pattern was similar to that of injection fluid containing a solvilizing agent, in which the DEHP concentration in the EL solution increased linearly over time at first and thereafter reached a plateau. 170 μg of the DEHP was dissolved after 200mL of the EL solution had passed through the PVC administration set (the drip conditions were 25°C, 100mL/hr, tube length 115cm and inner diameter 0.3cm). The amount of DEHP which dissolved into the solution depended on the temperature (25-40°C), and no clear difference was observed between the PVC tubes (administration tube, feeding tube). In addition, the amount of DEHP that dissolved into the solution varied depending on the type of enteral nutrition.

著者

河野 彬 菅田 節朗 原 泰寛 田中 睦子 加留部 喜晴 松島 美一

出版者

The Pharmaceutical Society of Japan

雑誌

Chemical and Pharmaceutical Bulletin (ISSN:00092363)

巻号頁・発行日

vol.31, no.5, pp.1666-1669, 1983-05-25 (Released:2008-03-31)

参考文献数

19

被引用文献数

2

---

A sensitive method for the assay of pyrimidine nucleoside phosphorylases in preparations of human and animal tissues by determination of pyrimidines is described. Pyrimidines formed enzymatically from thymidine, uridine, 5-fluorouridine, and 5'-deoxy-5-fluorouridine are determined by means of high-performance liquid chromatography with ultraviolet (UV) detection. The pyrimidines, after extraction with ethyl acetate, are separated by reversed-phase chromatography on μ-Bondapak C-18/Porasil. The limits of detection are 2.5, 1.0, and 2.0 pmol for thymine, uracil, and 5-fluorouracil, respectively.

著者

山下 正文 橋本 隆寿 平川 俊彦 福島 武雄 朝長 正道 原 泰寛 河野 彬 田中 睦子

出版者

The Japan Neurosurgical Society

雑誌

Neurologia medico-chirurgica (ISSN:04708105)

巻号頁・発行日

vol.25, no.8, pp.613-619, 1985-08-15 (Released:2006-09-21)

参考文献数

17

被引用文献数

1 2

---

To evaluate the usefulness of 5'-deoxy-5-fluorouridine (5'-DFUR) therapy for brain tumor, the pharmacokinetics of 5'-DFUR and 5-fluorouracil (5-FU) in the tumor, in the white matter surrounding the tumor and in the serum were investigated, and the thymidine phosphorylase, the main activating enzyme of 5'-DFUR in human tissues, was also studied. Materials were obtained from 24 cases of primary brain tumors and from 4 cases of metastatic carcinoma. During the operation 500 or 1, 000 mg of 5'-DFUR was administrated intravenously, and blood, tumor tissue and white matter were taken mainly within 60 minutes and partly within 180 minutes after intravenous administration of 5'-DFUR. In some cases samplings were performed serially. Concentrations of 5'-DFUR and 5-FU were measured by high performance liquid chromatography, and thymidine phosphorylase activity in tissue extracts was obtained against d-thymidine and/or 5'-DFUR as substrates. The concentrations of 5'-DFUR and 5-FU in serum decreased immediately in an exponential mode after intravenous administration of 1, 000 or 500 mg of 5'-DFUR. High concentrations of 5'-DFUR and 5-FU in the tumor tissues were noticed in malignant tumors, such as glioblastoma, ependymoma and chondrosarcoma, and 5-FU concentrations in the tumor in two cases of glioblastoma and one of ependymoma were higher than that in their sera. An important characteristic of 5'-DFUR was that it was converted to 5-FU in various tissues predominantly in malignant neoplasms. Thymidine phosphorylase activity was more prominent in glioblastoma, metastatic carcinoma and chordoma. Although the 5'-DFUR concentration in white matter was considerable, the 5-FU concentration was negligible suggesting low enzyme activity. An effect of 5'-DFUR therapy on malignant brain tumor should be expected from the high concentration of 5' DFUR and 5-FU in the tumor tissue. However, these high concentrations rapidly decreased, therefore, the appropriate mode of prescription of 5'-DFUR should be considered in clinical practice.